Morphogen-IX has developed protein-engineered forms of bone morphogenetic protein 9 (BMP9), conferring potent protection of the blood vessels in the lung, whilst lacking the bone-inducing properties of the native protein. BMP9 has shown strong preclinical efficacy in the reversal of PAH. This approach is based on targeting the central pathway underlying PAH identified in human genetic studies, pioneered in the British Heart Foundation-funded laboratory of Professor Nick Morrell at the University of Cambridge, who is now CEO at Morphogen-IX, together with co-founders Dr Wei Li and Dr Paul Upton. The company, founded in 2015, operates a virtual research and development model from its headquarters on the Babraham Research Campus, south of Cambridge, UK.
The Dinosaur Trust is proud to have funded projects that have been integral to the recent developments with Morphogen-IX. The excerpt above is from http://www.morphogen-ix.com/news.html – please visit this site for more information.